High-dose chemotherapy with allogeneic hematopoietic stem cell transplantation (allo-HSCT) can produce long-term remission in patients with higher-risk myelodysplastic syndromes (HR-MDS) and chronic myelomonocytic leukemia (CMML). However, this treatment regimen is not appropriate for elderly and/or comorbid patients; in these cases, azacitidine is a standard treatment. This systematic review was conducted to evaluate real-world evidence of treatment options for patients with HR-MDS/CMML. Medline and Embase (January 2006 to May 2016) were searched, in addition to conference proceedings and treatment guideline reviews. Studies on clinical effectiveness/efficacy outcomes with a sample size 50 patients were included. From 1061 unique citations identified, 87 full-text articles were reviewed, of which 24 articles reported at least 1 outcome of interest. Studies showed that HR-MDS/CMML patients treated with a conventional chemotherapy regimen (CCR) have poorer overall survival (OS). Key findings from individual HR-MDS studies showed improved survival with azacitidine over CCRs and higher overall response rates with clofarabine relative to low-dose cytosine arabinoside (but no significant difference in 2-year OS favoring clofarabine). OS was highest for patients treated with allo-HSCT. Findings indicate limited real-world data on treatment strategies available for HR-MDS/CMML patients. Most studies address the effect of chemotherapy or allo-HSCT on clinical outcomes, so are not applicable to elderly/comorbid patients who are too frail for those treatments. In particular, our analysis revealed limited evidence on viable options after failure of treatment with azacitidine, identifying a significant unmet need in this patient population.
Introduction
Myelodysplastic syndromes (MDS) are a group of hematological malignancies with an estimated incidence rate of 5.3 to 13.1 cases per 100,000 persons in the United States 1 and a median age of diagnosis of 71 to 76 years. 2 Transformation to acute myeloid leukemia (AML) occurs in approximately 10% and 70% of lower-and higher-risk (HR) patients, respectively. 3 MDS is categorized pathologically on the basis of morphology, cytochemistry, 4 immunophenotype, genetics, and clinical features.
Patients with HR disease have a poor prognosis and might not be candidates for some treatments because of advanced age and/or comorbidities.
and biological features with MDS, including cytopenia and bone marrow failure, risk of progression to AML, and overlapping, recurring, cytogenetic abnormalities. Indeed, epidemiological studies estimate that approximately 10% of diagnosed MDS cases should have been diagnosed as CMML. 9 As with MDS, HR CMML patients have a poorer prognosis compared with patients with lower-risk disease. 10 Diagnostic criteria for pathological categorization have been developed for MDS as well as CMML. However, those categorizations do not increase predictability in patient clinical outcomes; a high degree of variability is still observed in both conditions. In an effort to better predict an individual's risk for transformation to AML and to inform treatment goals and regimens, risk-based stratification systems have been developed. 11 The International
Prognostic Scoring System (IPSS), revised to the IPSS-R in 2012, is used to assign individuals to different risk stratification categories on the basis of the percentages of bone marrow myeloblasts, cytogenetics, and significant cytopenias. 11 The IPSS-R defines 5 risk groups: HR disease is defined as IPSS-R scores of intermediate, high, or very high, which are predictive of lower survival outcomes and higher likelihood of transformation to AML. 11 Treatment goals and regimens are on the basis of whether an individual is considered to be lower-risk or HR.
11
The National Comprehensive Cancer Network (NCCN) guidelines have outlined treatment strategies for MDS. CMML treatment recommendations generally follow those set for MDS or AML patients, 11 depending on the CMML classification. Current treatment options for patients with HR MDS (HR-MDS) and CMML include conventional chemotherapy regimens (CCRs), chemotherapy with hypomethylating agents (HMAs), and allogeneic (allo) hematopoietic stem cell transplantation (HSCT). 11 It is recommended that patients with HR-MDS and CMML who can tolerate a high-intensity therapy be treated with intensive induction chemotherapy and/or allo-HSCT. 11 Allo-HSCT is the only potentially curative treatment, but eligibility is limited by older age and comorbidities. Azacitidine and decitabine are the only 2 HMAs approved for treating patients with HR-MDS. 11 Azacitidine, initially approved by the Food and Drug Administration in 2004 for treatment of MDS, was given expanded approval in 2009 to reflect new overall survival (OS) data from the AZA-001 study in patients with HR-MDS. 12 In that study, azacitidine showed significant and clinically meaningful prolongation of OS in HR-MDS patients, with a median OS of 24.5 months compared with 15.0 months with conventional care (best supportive care [BSC], low-dose cytarabine, or intensive chemotherapy). Although azacitidine and decitabine are considered to be similar on the basis of their mechanism of action, no head-tohead trials have compared their effectiveness. 11 Azacitidine remains the preferred treatment because of the improved survival of HR-MDS patients observed in AZA-001.
Overall, there is a lack of clinical evidence regarding effective treatments for HR-MDS/CMML patients, and current guideline therapies in real world practice settings have not confirmed the survival benefits identified in pivotal trials. Furthermore, there is limited knowledge regarding health care resource utilization and economic burden for these patient populations. As a result, this review was designed to systematically collect and review real-world evidence for treatment patterns and outcomes associated with therapies used to treat patients with HR-MDS or CMML.
Materials and Methods
Conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, the goal of our systematic literature review (SLR) was primarily to identify real-world evidence of effectiveness among heterogeneous sets of patients in real life practice settings; because search algorithm structures did not target HR-MDS/CMML randomized controlled trials (RCTs), only a few were located. The MEDLINE and Embase electronic databases were searched using a prospective protocol to identify studies published between January 1, 2006 and May 11, 2016 that reported HR-MDS/CMML treatment outcomes. The term "higher-risk" was author-defined, and consequentially, the specific cutoffs as well as risk scores used to define the HR-MDS subset of patients varied from study to study.
In addition to the 2 databases, we reviewed conference abstracts for the 2 most recent meetings of the American Society of Clinical Oncology, European Society for Medical Oncology, American Society of Hematology, European Hematology Association, International Symposium on Myelodysplastic Syndromes, and International Society for Pharmacoeconomics and Outcomes Research (international as well as European annual meetings).
We also reviewed the National Guidelines Clearinghouse and NCCN guidelines to identify the most recent, relevant clinical practice guidelines.
Appendix A shows the search algorithm implemented for the search in Embase. Analogous search terms, algorithms, and limits were used to conduct the searches in MEDLINE (via PubMed).
The screening process began with an investigator screening all titles and abstracts against the study inclusion/exclusion criteria, using the Participants, Interventions, Comparisons, Outcomes, Study Design, and Time Period elements (Table 1) . A second Treatment Effectiveness in HR-MDS/CMML investigator double-checked 10% of the rejected abstracts to confirm accuracy. The full-text articles still of interest were retrieved and screened. All excluded studies were confirmed; any discrepancies were resolved by an independent investigator. To be included, all accepted articles had to meet the inclusion criteria: articles in English focused on adult patients with HR-MDS or CMML in an RCT or observational study (prospective or retrospective) that reported outcomes of clinical effectiveness/efficacy (OS, treatment response rate, or duration of response).
Full data extraction was performed on all articles included.
Results Figure 1 shows the PRISMA diagram of study attrition. After applying all criteria to the 1061 unique citations identified, 24 articles, 3, reporting on 22 studies, examined efficacy and/or effectiveness of therapy in patients with HR-MDS or CMML. Because the search criteria were tailored to identify real-world evidence, 18 of the studies (82%) used observational study designs, whereas 4 (18%) were RCTs. One study took place in Japan; the remainder were in the United States and/or Europe.
Higher-Risk MDS
As noted previously, a high degree of variability across study populations and specific subgroups, including age, number of previous therapy lines received, and distribution across IPSS risk categories, made comparisons across studies difficult. Data on the 18 HR-MDS trials are shown in Table 2 . 3, [13] [14] [15] [16] [18] [19] [20] [21] [22] [23] [26] [27] [28] [29] [30] [32] [33] [34] Chemotherapy: Conventional Chemotherapy Regimens Overall, the prognosis of patients treated with CCRs in realworld settings was poor, particularly with respect to longer-term OS. Among patients receiving CCRs, 2 studies, Bernal et al 13 and
Kantarjian et al 23 reported median OS of 12.2 and 34 weeks (3 and 8.5 months), respectively. Longer-term survival among patients receiving CCRs was low, with 3-and 5-year OS rates of only 19% 30 and 8%, 22 respectively.
In 1 RCT, 2-year OS rates were similar among patients receiving low-dose cytosine arabinoside (LD-AraC; 12%) versus clofarabine (13%). 14 In the subset of patients achieving complete response (CR), OS was higher with 2-year rates from CR at 44% for LDAraC and 26% for clofarabine (P ¼ .5 One study (Kantarjian et al 22 ) reported survival for patients who underwent allo-HSCT after chemotherapy (cytarabine with or without topotecan with or without cyclophosphamides, or fludarabine with or without anthracyclines); those who had the procedure while experiencing a first CR had a higher estimated 5-year survival rate (36%) than those who underwent the procedure after a first CR failed (9%).
The CCR was the treatment in the only 2 studies that reported rates of progression to AML; Bernal et al 13 
Chemotherapy with HMAs
Ten observational studies (11 articles) reported patient survival rates (Table 2) 13 There were limited data on progression-free survival (PFS), with some partial evidence suggesting treatment with HMAs might delay disease progression. One study reported a median PFS of 31.5 months in patients treated with azacitidine. 26 Overall response (OR) and, in particular, CR, are important end points in blood cancers, because they are associated with fewer infections, and less bleeding or need for supportive care. 36 Response rates were reported in 5 studies. The CR rates ranged from 37% (Kantarjian et al 22 ) to 55% (Cabrero et al 15 ) for therapy with HMA and allo-HSCT after induction. In HR-MDS with chromosome 7 abnormality, the CR rate was only 16.4% in patients treated with azacitidine with an OR rate (ORR) of 42.8%. 16 ORR was similar among patients treated with HMAs alone (43%) compared with patients treated with allo-HSCT after HMA (45%). 15 Durable CR, often considered an established end point of clinical benefit in leukemia, was reported in only 1 observational study, with 16% experiencing CR for at least 5 years.
Rates of CR varied widely from 0% 34 to 26% 3 for patients with hypocellular bone marrow treated with azacitidine and all patients treated with intravenous clofarabine, respectively. In Burnett et al, 14 OR for clofarabine (38%) was nearly double that of LD-AraC (19%; P < .001), although clofarabine did not improve OS.
Allogeneic HSCT
Provision of allo-HSCT is very expensive for health care systems because it is a highly specialized and labor-intensive procedure that requires prolonged isolation of the patient within specialized hospital facilities, with a high requirement for blood products and expensive medications. 37 We examined rates of allo-HSCT after treatment with previous therapy in the studies included in this review. Four studies in HR-MDS reported rates of allo-HSCT ranging from 6% to 14%. 18, 22, 29, 33 Despite the fact that populations and previous treatments received were variable across studies, rates of allo-HSCT after therapy were fairly consistent. The study reporting the lowest rate examined patients treated with azacitidine who underwent allo-HSCT before their third treatment cycle 18 ; additionally, only 22% of patients in this study were classified as high-risk according to IPSS. Prébet et al 33 in 2011 examined rates of allo-HSCT after failure with azacitidine therapy, and reported that these cases had the highest rate of allo-HSCT (37 patients [14%]). Of the patients enrolled in this study, 106 [40%] were classified as having a high IPSS risk score. Median OS among patients who received allo-HSCT after azacitidine failure was 19 months. Pavesi et al reported that 98% of patients treated with allo-HSCT had experienced CR at day 28. 32 This study population had a median age of 60 years; approximately 40% were already in CR at the time of allo-HSCT. 32 In another study, OS in adults ages 18 to 39 years was compared with OS in patients older than 39 years. 21 Median OS was 82 months in the younger group compared with 17 months in the older group (P ¼ .001). This study reported the highest median OS estimate of all the studies included in this review. Interestingly, no statistically significant difference was observed for the subset of patients who underwent transplantation; the median OS was 55 months in adults and adolescents, and 46 months in older patients (P ¼ .4). Gerds et al 2015 20 reported that high-/very high-risk patients who received umbilical cord blood transplantation were more likely to die from any cause (relative risk [RR], 1.55; P ¼ .01) and also more likely to experience relapse (RR, 1.39; P ¼ .04) compared with those classified as having very low-/low-risk disease.
Chronic Myelomonocytic Leukemia
Of 24 articles in this review, only 5 reported results for CMML (Table 3) 17,24,25,31,35 ; those represented 4 observational studies, only 1 of which had more than 85 patients (n ¼ 513; Symeonidis et al 35 ) .
One study (reported in Kongtim et al 24 and Kongtim et al 25 ) reported survival rates for CMML patients who received chemotherapeutic agents before allo-HSCT-3-year OS rates of 45% versus 39% (P ¼ .22, not significant), and 3-year PFS rates of 43.2% versus 27.4% (P ¼ .04), for HMAs versus CCRs, respectively. 24, 25 Three studies 17, 31, 35 evaluated allo-HSCT in CMML patients.
Consistent results were reported across the studies; OS at 3 and 4 years was 32% 31 and 33%, 35 respectively. Eissa et al reported a median OS of 5.2 years (range, 0.5-19.1 years). 17 Symeonidis et al 35 reported no significant differences in relapse-free survival or OS at 4 years on the basis of World Health Organization 2000 or 2008 classifications of CMML-1 and CMML-2. Cumulative incidence of relapse at 4 years was lower for patients with a normal karyotype compared with those with an abnormal one (35% vs. 49%; P ¼ .07). However, 4-year OS and relapse-free survival were not significantly different between patient subgroups. 35 Finally, Eissa et al 17 showed that relapse correlated with poor cytogenetics and with risk determined according to the MD Anderson Prognostic score. In addition, the authors also reported statistically significant associations between poor cytogenetics and nonrelapse mortality (hazard ratio, 3.09; P ¼ .02) and overall mortality (hazard ratio, 2.73; P ¼ .004).
Discussion
This first SLR to explore real-world effectiveness of treatment regimens specifically for patients with HR-MDS or CMML began with >1000 unique citations that were reduced to only 24 articles (representing 22 studies). Because the review goal was real-world information, the data included in this analysis came from 18 observational studies; 4 RCTs were also included.
Survival outcomes were reported across all modes of treatment; patients who received chemotherapy alone had much shorter OS than did those who received allo-HSCT. Among studies that examined chemotherapy, the highest median OS reported was 34 months, in a study of azacitidine. 26, 27 In the allo-HSCT setting, Grabska et al 21 reported 46-month median OS for older patients, significantly lower than younger patients' 55-month median. For CMML patients, median OS was 62 months. 17, 21 The best chance for achieving long-term remission for HR-MDS/CMML patients is currently offered by allo-HSCT. However, the procedure is performed in only a fraction of potential patients-the median age range was 52 to 60 years for patients enrolled in studies of allo-HSCT, substantially lower than the 68-to 74-year median age range reported for the patients in studies of HMA/azacitidine. There was some comparative evidence from 1 RCT suggesting better survival with azacitidine compared with a CCR. 34 Another RCT reported improved survival with rigosertib over BSC in the second-line setting after failure with primary HMAs. 19 Although rigosertib improved survival by only a few months, the result is encouraging, because dismal outcomes often follow failure of azacitidine treatment, and only approximately one-half of patients achieve objective response. 38 Data on outcomes related to PFS or AML progression were much more limited, and were reported in only a quarter of the studies included in this review. One observational study that compared azacitidine with CCR observed no difference in the rate of AML progression. 13 Overall response and CR outcomes were reported in one-half of the studies. Only 1 HR-MDS study of allo-HSCT reported CR rates; these ranged from 84% to 98%. 32 Studies that evaluated HMA therapy reported much lower CRs of 37% to 55%. 15 By design, all studies in this review included a sample size of at least 50 patients. However, 60% of studies enrolled 200 or more patients. An adequate sample size is important; many of the studies with 100 or fewer patients were single-arm studies in which the purpose was to establish a response as proof of concept for a therapy under investigation. Several of the observational studies included in this review compared effectiveness across 2 or more treatment regimens. 13, 15, 24, 28 Although observational studies by design cannot completely eliminate selection bias, and are hence considered inferior to RCTs, most did use multivariate methods in an effort to reduce these sources of bias. In addition, observational studies not only can offer important insights into the use and effectiveness of therapies in real-world settings, but also can often be complementary to RCTs. In this SLR we sought to identify studies of patients with HR-MDS or CMML; however, much of the published literature included mixed populations of HR-MDS patients within a broader, lower-risk MDS population, or CMML patients among a broader AML population, with no discernible reporting of outcomes according to disease identity or severity. When subgroup results were presented for a population of interest, often the patient numbers were too low to show a data trend. This was further compounded by the variation in classification systems used to define "high risk" patients; these have evolved over time to incorporate not just clinical features but also transfusion requirements and prognostic factors.
Conclusion
Overall, these results indicate there are limited real-world data regarding approved treatment strategies and associated clinical outcomes in patients with HR-MDS or CMML. The reviewed studies focused on patient outcomes associated with chemotherapy and/or stem cell transplantation. Patients ineligible for these treatments because of age or comorbidities, and related poor response, are not represented in these studies, which might limit broader application of the findings. The variability observed in study design, patient characteristics, risk-based disease scoring/classification, and numbers of previous therapeutic regimens complicates interpretation of the relative merit of therapeutic regimens. Although prognosis varied among studies, it was generally poor, and the data related to survival and response outcomes were insufficient to identify an optimal therapeutic approach, aside from allo-HSCT.
There is a general lack of data suitable to inform health care decisions and practices regarding patient care. In particular, the appropriateness of allo-HSCT as a treatment for older adults and the role of lower-intensity therapies such as azacitidine or decitabine as alternative options are still unclear. Our analysis shows the paucity of viable treatment options for older patients. This represents a critical, unmet medical need, especially because these conditions are most commonly diagnosed in elderly patients. Additional studies on the use of allo-HSCT in older adults along with a delineation of exclusionary factors are necessary to fill this knowledge gap.
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